- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| PHARMALA BIOTECH Aktie jetzt für 0€ handeln | |||||
| 08.08. | Pharmala Biotech Holdings Inc: Pharmala delivers 500 capsules of MDMA to Merhavim | 2 | Stockwatch | ||
| 07.08. | PharmAla Biotech: PharmAla Delivers MDMA to Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License | 1 | GlobeNewswire (USA) | ||
| 26.07. | Pharmala Biotech Holdings Inc: Pharmala omits Q3 net P&L in NR, talks expenses | 2 | Stockwatch | ||
| 25.07. | PharmAla Biotech: PharmAla Issues Q3 Financial Statements | 587 | GlobeNewswire (Europe) | TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 20.06. | Pharmala Biotech Holdings Inc: Pharmala files prospectus to issue $50M of securities | 1 | Stockwatch | ||
| 20.06. | PharmAla Biotech: PharmAla Files Preliminary Base Shelf Prospectus | 1 | GlobeNewswire (USA) | ||
| 04.06. | Pharmala Biotech Holdings Inc: Pharmala completes shipment of LaNeo MDMA to Yale | 2 | Stockwatch | ||
| 03.06. | PharmAla Biotech: PharmAla Completes Shipment of LaNeo MDMA to Yale University, Provides Investor Update | 1 | GlobeNewswire (USA) | ||
| 30.05. | Pharmala Biotech Holdings Inc: Pharmala sniffs out counterfeit nasal spray on-line | 2 | Stockwatch | ||
| 30.05. | PharmAla warns against fake MDMA products bearing its name | 1 | The Market Herald Canada | ||
| 30.05. | PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla | 162 | GlobeNewswire (Europe) | TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing... ► Artikel lesen | |
| 15.05. | PharmAla Biotech Launches Phenesafe AI Drug Discovery Platform for Novel Phenethylamines | 3 | GlobeNewswire (USA) | ||
| 30.04. | PharmAla Biotech: PharmAla Issues Q2 Financial Statements | 1.144 | GlobeNewswire (Europe) | TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 24.03. | Pharmala Biotech Holdings Inc: Pharmala contracts third party logistics outfit in U.S. | 3 | Stockwatch | ||
| 24.03. | PharmAla Biotech: PharmAla Contracts with Partner to Act as US Distributor | 3 | GlobeNewswire (USA) | ||
| 21.03. | Pharmala Biotech Holdings Inc: Pharmala ships LaNeo MDMA to University of Washington | 3 | Stockwatch | ||
| 21.03. | PharmAla Biotech: PharmAla Completes Shipment of LaNeo MDMA to the University of Washington | 2 | GlobeNewswire (USA) | ||
| 10.03. | Pharmala Biotech Holdings Inc: Pharmala enters Dutch distribution deal with Duchefa | 1 | Stockwatch | ||
| 10.03. | PharmAla Biotech: PharmAla Signs Duchefa Farma as Exclusive Distributor in Netherlands | 287 | GlobeNewswire (Europe) | TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and... ► Artikel lesen | |
| 04.03. | Pharmala Biotech Holdings Inc: Pharmala completes shipment of LaNeo MDMA to UCLA | 1 | Stockwatch |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,960 | -0,24 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Qiagen nach Zahlen von 54 auf 57 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Tycho Peterson attestierte dem... ► Artikel lesen | |
| EVOTEC | 6,356 | -2,37 % | Plattform-Strategien krempeln Biotech-Markt um: BioNxt, Thermo Fisher Scientific, Evotec | Bei Biotech gilt längst nicht mehr das Prinzip alles oder nichts. Statt nur ein Produkt im Angebot zu haben, setzt sich bei der Entwicklung der Wirkstoffe von morgen die Plattform-Ökonomie durch. Was... ► Artikel lesen | |
| DYNE THERAPEUTICS | 12,380 | -1,12 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 46,550 | +1,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| BOLT PROJECTS | 8,910 | +4,82 % | Pre-market Movers: Sonoma Pharmaceuticals, Bolt Projects, Ibotta, TeraWulf, 180 Life Sciences | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Sonoma Pharmaceuticals, Inc. (SNOA) is up over... ► Artikel lesen | |
| BIONTECH | 97,00 | -0,05 % | Pharma und Biotech News bei Eli Lilly, NetraMark, BioNTech und Curevac | Der neue US-Gesundheitsminister Robert F. Kennedy setzt nach und nach mehr Akzente in der US-amerikanischen Gesundheitspolitik. Zuletzt verbot der Gesundheitsminister den Einsatz der Quecksilberverbindung... ► Artikel lesen | |
| ITEOS THERAPEUTICS | 10,105 | -0,05 % | iTeos Therapeutics Inc.: iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right | WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement... ► Artikel lesen | |
| VALNEVA | 4,730 | -0,76 % | Valneva: Operativer Cashburn deutlich verringert - Umsatz steigt | Valneva hat im ersten Halbjahr 2025 die Gesamterlöse um 37,8 Prozent auf 97,6 Millionen Euro gesteigert. Der Umsatz aus Produktverkäufen stieg um 33,3 Prozent auf 91 Millionen Euro. Das Unternehmen... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,765 | +2,22 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 14,540 | +0,48 % | ARS Pharmaceuticals stock maintains Strong Buy rating at Raymond James on strong neffy sales | ||
| IMMUNOME | 10,280 | +3,32 % | Immunome Inc. - 10-Q, Quarterly Report | ||
| LENZ THERAPEUTICS | 37,870 | -7,43 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,690 | +0,91 % | Summit Therapeutics: Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025 | Ivonescimab to be Featured at WCLC Presidential Symposium for Second Consecutive Year
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that data from the... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 4,520 | +1,80 % | Vir Biotechnology, Inc.: Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart elebsiran without or with PEG-IFNa, respectively As previously... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 6,820 | +3,33 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives... ► Artikel lesen |
Das Unternehmen PHARMALA BIOTECH HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PHARMALA BIOTECH HOLDINGS INC finden Sie auf Wallstreet Online.